Health Science Leaders Join Forces to Accelerate Development of Treatments for Neurological Diseases
Montreal, Quebec and Vancouver, British Columbia – Working together to accelerate research into neurological diseases, three leading players in Canada’s health sciences sector are joining forces in a unique multi-million dollar partnership to create a novel drug development platform that will help advance new therapeutics for some of the most debilitating conditions such as amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, and Parkinson’s disease.
Merck Canada announced yesterday the allocation of a total of $16 million in grants to Quebec’s four faculties of medicine. McGill, along with Université de Montréal, Université de Sherbrooke and Université Laval will each receive $4 M to support health research with a translational component conducted in areas of unmet medical need. The announcement was made in Quebec City at the BioContact Quebec Biopharmaceutical Partnership Symposium, in the presence of Dr. Thomas R. Cannell, President and Managing Director, Merck Canada Inc., and of Pierre Duchesne, Minister of Higher Education, Research, Science and Technology.